Identification of a novel coronavirus in patients with severe acute respiratory syndrome by Drosten, C. (Christian) et al.
 n engl j med 
 
348;20
 
www.nejm.org may 
 
15, 2003
 
The
 
 new england journal 
 
of
 
 medicine
 
1967
 
original article
 
Identification of a Novel Coronavirus in Patients 
with Severe Acute Respiratory Syndrome
 
Christian Drosten, M.D., Stephan Günther, M.D., Wolfgang Preiser, M.D., 
Sylvie van der Werf, Ph.D., Hans-Reinhard Brodt, M.D., Stephan Becker, Ph.D., 
Holger Rabenau, Ph.D., Marcus Panning, M.D., Larissa Kolesnikova, Ph.D., 
Ron A.M. Fouchier, Ph.D., Annemarie Berger, Ph.D., Ana-Maria Burguière, Ph.D., 
Jindrich Cinatl, Ph.D., Markus Eickmann, Ph.D., Nicolas Escriou, Ph.D., 
Klaus Grywna, M.Sc., Stefanie Kramme, M.D., Jean-Claude Manuguerra, Ph.D., 
Stefanie Müller, M.Sc., Volker Rickerts, M.D., Martin Stürmer, Ph.D., Simon Vieth, 
Hans-Dieter Klenk, M.D., Albert D.M.E. Osterhaus, Ph.D., 
Herbert Schmitz, M.D., and Hans Wilhelm Doerr, M.D.
 
From the Bernhard Nocht Institute for Trop-
ical Medicine, National Reference Center
for Tropical Infectious Diseases, Hamburg
(C.D., S.G., M.P., K.G., S.K., S.M., S.V.,
H.S.); the Institute of Medical Virology
(W.P., H.R., A.B., J.C., M.S., H.W.D.) and the
Medical Clinic III (H.-R.B., V.R.), Johann
Wolfgang Goethe University, Frankfurt am
Main; and the Institute of Virology, Phil-
ipps University, Marburg (S.B., L.K., M.E.,
H.-D.K.) — all in Germany; the Pasteur In-
stitute, Molecular Genetics of Respiratory
Tract Viruses, National Influenza Center
(Northern France), Paris (S.W., A.-M.B.,
N.E., J.-C.M.); and the Institute of Virology,
Erasmus University, Rotterdam, the Neth-
erlands (R.A.M.F., A.D.M.E.O.). Address
reprint requests to Dr. Drosten at the De-
partment of Virology, Bernhard Nocht
Institute for Tropical Medicine, Bernhard-
Nocht Str. 74, 20359 Hamburg, Germany,
or at drosten@bni-hamburg.de. 
Drs. Drosten and Günther contributed
equally to this article.
This article was published at www.nejm.org
on April 10, 2003.
N Engl J Med 2003;348:1967-76.
 
Copyright © 2003 Massachusetts Medical Society.
 
background
 
The severe acute respiratory syndrome (SARS) has recently been identified as a new
clinical entity. SARS is thought to be caused by an unknown infectious agent.
 
methods
 
Clinical specimens from patients with SARS were searched for unknown viruses with
the use of cell cultures and molecular techniques. 
 
results
 
A novel coronavirus was identified in patients with SARS. The virus was isolated in cell
culture, and a sequence 300 nucleotides in length was obtained by a polymerase-chain-
reaction (PCR)–based random-amplification procedure. Genetic characterization in-
dicated that the virus is only distantly related to known coronaviruses (identical in 50 to
60 percent of the nucleotide sequence). On the basis of the obtained sequence, conven-
tional and real-time PCR assays for specific and sensitive detection of the novel virus
were established. Virus was detected in a variety of clinical specimens from patients
with SARS but not in controls. High concentrations of viral RNA of up to 100 million
molecules per milliliter were found in sputum. Viral RNA was also detected at extremely
low concentrations in plasma during the acute phase and in feces during the late con-
valescent phase. Infected patients showed seroconversion on the Vero cells in which
the virus was isolated. 
 
conclusions
 
The novel coronavirus might have a role in causing SARS. 
abstract
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he severe acute respiratory syn-
 
drome (SARS) was recently identified as a
new clinical entity.
 
1,2
 
 Patients present with
fever, dry cough, dyspnea, headache, and hypox-
emia. Typical laboratory findings are lymphopenia
and mildly elevated aminotransferase levels. Death
may result from progressive respiratory failure due
to alveolar damage.
 
3
 
 SARS appears to be caused by
an unknown infectious agent that is transmitted
from human to human. The World Health Organi-
zation (WHO) had recorded 2353 cases by April 4,
2003. About 4 percent of patients with SARS have
died.
 
4
 
 The SARS epidemic started in Asia, with the
majority of cases occurring in China and the Asia–
Pacific region. The epidemic has spread from Asia to
other continents through international travel. The
WHO has established a network of international
laboratories to facilitate the identification of the
causative agent of SARS. As part of this network,
we have identified and characterized a novel coro-
navirus in patients with SARS. 
 
patients and samples
 
The index patient was a 32-year-old male physician.
From March 3 to 9, 2003, he treated a patient with
atypical pneumonia in Singapore who had arrived
from Hong Kong. On March 9 (day 1) his illness
started with abrupt onset of fever (temperature,
39.4°C), when he was in New York. On day 4, a dry
cough and a sore throat developed, along with
erythema on the trunk. During a stopover in Frank-
furt, Germany, on his flight to Singapore, he was
transferred to an isolation unit at the Frankfurt Uni-
versity Hospital with suspected SARS (day 7). He had
hypoxemia (partial pressure of oxygen in arterial
blood, 59 mm Hg) and required oxygen supple-
mentation. Chest radiography showed worsening
bilateral opacifications. Laboratory abnormalities
included elevated levels of aspartate aminotrans-
ferase (46 U per liter) and lactate deydrogenase
(478 U per liter) and an elevated maximal C-reac-
tive protein level (30.7 mg per deciliter), as well as
leukopenia and lymphopenia. Convalescence began
on day 10. Treatment involved levofloxacin, vanco-
mycin, imipenem, doxycycline, and oseltamivir.
Two contacts of the index patient (Contacts 1 and
2) were isolated as well. Contact 1, the patient’s
wife, reported a headache after admission (March
15, day 1). Fever (temperature, 38.2°C) and myalgia
developed on day 2. The temperature decreased dur-
ing days 5 and 6, but on day 7 fever developed again
and there were crackles over her lungs, accompa-
nied by dry cough and hypoxemia (partial pressure
of oxygen in arterial blood, 65 mm Hg). Convales-
cence began on day 9. Laboratory abnormalities in-
cluded a maximal C-reactive protein level of 1.5 mg
per deciliter, leukopenia, and lymphopenia. Ther-
apy comprised erythromycin and ceftriaxone.
Contact 2, the mother of Contact 1, had head-
ache and myalgia on March 13 (day 1) and sore
throat and fever (temperature, 38.2°C) on day 2. Fe-
ver disappeared on day 3. She reported burning pain
in the eyes on days 4 and 5. There were no patholog-
ic findings on chest radiography. Pathologic labo-
ratory findings included a maximal C-reactive pro-
tein level of 9.9 mg per deciliter, an increase in the
aspartate aminotransferase level to 154 U per liter,
and an increase in the lactate dehydrogenase level
to 319 U per liter between days 9 and 16. Therapy
involved imipenem, levofloxacin, doxycycline, and
oseltamivir.
A total of 49 specimens from 18 patients with
suspected or probable SARS, according to the WHO
case definition, and from 21 healthy contact per-
sons were sampled between March 5 and March 27,
2003, during the SARS epidemic in Hanoi, Viet-
nam.
 
2
 
 A total of 54 stool samples from patients in
Germany were available as controls.
 
microbiologic and virologic testing for 
typical and atypical respiratory pathogens
 
Respiratory and blood specimens from the patients
in Frankfurt were tested by polymerase chain reac-
tion (PCR) with specific primers for 
 
Mycoplasma
pneumoniae, Chlamydia pneumoniae,
 
 human cytomeg-
alovirus, adenoviruses, respiratory syncytial virus,
parainfluenzavirus types 1, 2, 3, and 4, Hendra vi-
rus, Nipah virus, human metapneumovirus, influ-
enzaviruses A and B, rhinovirus, and human coro-
navirus strains OC43 and 229E, as well as with
universal primers for herpesviruses, arenaviruses,
bunyaviruses, enteroviruses, alphaviruses, flavivi-
ruses, filoviruses, and paramyxoviruses. Respiratory
specimens were also tested by antigen enzyme-
linked immunosorbent assay (ELISA) for 
 
M. pneu-
moniae,
 
 influenzaviruses A and B, and respiratory
syncytial virus. Antigen ELISA for legionella species
was performed with urine. Paired serum samples
were tested serologically for 
 
C. pneumoniae
 
 (IgA and
IgG), 
 
C. trachomatis
 
 (IgA and IgG), 
 
C. psittaci
 
 (IgG),
t
methods
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M. pneumoniae,
 
 
 
Coxiella burnetii,
 
 influenzaviruses A
and B (IgG and IgA), dengue virus (IgG and IgM),
measles virus (IgG and IgM), hantaviruses, adeno-
viruses, parainfluenzavirus types 1, 2, and 3, and
respiratory syncytial virus. 
Electron microscopy was performed with nega-
tive staining of respiratory and blood samples. In
addition, cells in bronchoalveolar-lavage fluid were
analyzed with the use of ultrathin sections embed-
ded in Epon and LR Gold resins. Vero, Madin–Derby
canine-kidney, and A549 cells were inoculated with
respiratory and blood specimens from all three pa-
tients and grown under biosafety level 3 or 4 condi-
tions.
 
rna extraction
 
Sputum samples were shaken for 30 minutes with
an equal volume of acetylcysteine (10 g per liter)
and 0.9 percent sodium chloride. The resulting ho-
mogenate, native body fluids, resuspended swab
samples (in 1 ml of phosphate-buffered saline), or
tissue-culture supernatant was extracted with a viral
RNA kit (QIAamp, Qiagen; elution volume, 60 µl).
Stool specimens were extracted with the QIAamp
stool kit (Qiagen).
 
random reverse-transcriptase–pcr 
procedure
 
A volume of 2 µl of RNA solution was analyzed with
a random reverse-transcriptase (RT)–PCR assay. The
Superscript II platinum 
 
Taq
 
 polymerase one-step
RT-PCR kit (Invitrogen) was used for the reaction
(20 µl total volume). Reactions contained 10 µl of
buffer concentrate, 2 mM of magnesium sulphate,
0.8 µl of enzyme mixture, and 1.9 µM of each of two
primers. Fifteen primer pairs were used. Some of the
primers contained degenerate positions, and most
had a thymidine residue at their 3' ends to allow
DNA polymerase to work in spite of incomplete
nucleotide matches at the ends of the primers.
 
4
 
The primers were originally designed to target the
genome of yellow fever virus strain 17D and the
polymerase gene of Paramyxoviridae. Thermal cy-
cling comprised 42°C for 30 minutes; 95°C for
3 minutes; 10 cycles of 95°C for 10 seconds, 55°C
for 15 seconds (decreasing by 1°C per cycle), 72°C
for 40 seconds; 40 cycles of 95°C for 10 seconds,
56°C for 10 seconds, and 72°C for 40 seconds. Prod-
ucts were analyzed on a 1 percent agarose gel, gel-
purified, and reamplified with the use of the corre-
sponding primers but without degenerate positions.
Products were sequenced with the use of a didesoxy
terminator sequencing reaction (BigDye termina-
tor reaction mix, Applied Biosystems) and an auto-
mated DNA sequencer (model 3100, Applied Bio-
systems).
 
rt-pcr specific for the novel coronavirus
 
For diagnostic RT-PCRs, the Superscript II platinum
 
Taq
 
 polymerase one-step RT-PCR kit was used. De-
tails of the procedures are summarized in Table 1.
An RNA standard transcribed in vitro was generat-
ed by amplification of the target region with primers
BNIoutS2 and BNIoutAs. The fragment was cloned
and transcribed into RNA in vitro, essentially as de-
scribed elsewhere.
 
5
 
sequence and phylogenetic analysis
 
We searched for homologies to known sequences
using the nucleotide or translated data base of the
Basic Local Alignment Search Tool (BLAST) at http:
//www.ncbi.nlm.nih.gov:80/BLAST/. Phylogenetic
analysis was performed with the use of the Phyloge-
ny Inference Package (PHYLIP), version 3.57c.
 
6
 
microbiologic testing for common 
pathogens
 
A large number of tests for known respiratory
pathogens were performed with specimens from all
three patients in Frankfurt. The test results were
negative, except as follows.
Paramyxovirus-like particles were seen in throat
swabs and sputum samples from the index patient
by electron microscopy. The particles were scarce.
However, several PCR tests specific for virus species
of the family Paramyxoviridae were negative (includ-
ing tests for human metapneumovirus), as were
PCR assays based on primers designed to react
broadly with all members of that family. 
 
C. pneumoniae
 
 was not detected by PCR or antigen
ELISA in sputum of the index patient from day 9.
However, on day 11, electron microscopy of cells in
a bronchoalveolar-lavage specimen from the index
patient showed a severe intracellular bacterial infec-
tion, and the bronchoalveolar-lavage cells reacted in
immunofluorescence analyses with a monoclonal
antibody directed against 
 
C. pneumoniae
 
. Consistent
with this finding, there was an increase by a factor
of four in the 
 
C. pneumoniae
 
 IgA titer in the index pa-
tient between day 10 and day 13. 
results
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* Sequence was communicated through the World Health Organization’s SARS etiology network by colleagues from the Centers for Disease Control 
and Prevention (CDC).
† Formulation was included in the Superscript II reverse transcriptase (RT)/platinum 
 
Taq
 
 polymerase one-step RT-PCR kit (Invitrogen).
‡ Formulation was supplied with platinum 
 
Taq
 
 DNA polymerase (Invitrogen).
§ Formulation was supplied by Sigma.
¶Fluorescence was measured with the Roche LightCycler, F1 detection channel, and the Applied Biosystems 7000 SDS machine, FAM detection 
 
channel without passive reference dye.
 
Table 1. Primers and Protocols for Diagnostic Polymerase-Chain-Reaction Assays.
Protocol
No. Oligonucleotides Target and Fragment Length
 

 
Reagent Formulation Thermal Cycling Profile
 
1
 
IN-2*
 
ggg TTg ggA CTA TCC 
TAA gTg TgA
 
IN-4*
 
TAA CAC ACA AAC 
ACC ATC ATC A
CDC fragment
452 bp
10 µl 2¬ reaction buffer†
2.45 mM magnesium sulfate†
500 nM each primer
0.4 µl reverse-transcriptase/
 
Taq
 
 DNA polymerase 
mixture†
2 µl RNA
20 µl total volume
45°C, 30 min
95°C, 3 min
10 cycles of
95°C, 10 sec
60°C, 10 sec (decrease 
by 1°C per cycle)
72°C, 30 sec
40 cycles of
95°C, 10 sec
56°C, 10 sec
72°C, 30 sec
2
 
IN-6*
 
ggT Tgg gAC TAT
CCT AAg TgT gA
 
IN-7*
 
CCA TCA TCA gAT AgA
ATC ATC ATA
CDC fragment
440 bp
3
 
BNIoutS2
 
ATg AAT TAC CAA
gTC AAT ggT TAC
 
BNIoutAs
 
CAT AAC CAg TCg 
gTA CAg CTA
BNI-1 fragment
189 bp
4
 
SAR1S
 
CCT CTC TTg TTC 
TTg CTC gCA
 
SAR1As
 
TAT AgT gAg CCg 
CCA CAC Atg
CDC fragment 
nested PCR 
for protocols 1 and 2
121 bp
 

 
5 µl 10¬ reaction buffer‡
200 µM dNTP
2.5 mM magnesium chloride‡
200 nM each primer
1.25 units platinum 
 
Taq
 
 
polymerase‡
1 µl PCR product from previ-
ous round
50 µl total volume
95°C, 3 min
10 cycles of
95°C, 10 sec
60°C, 10 sec (decrease 
by 1°C per cycle)
72°C, 20 sec
20 cycles of
95°C, 10 sec
56°C, 10 sec
72°C, 20 sec
5
 
BNIinS
 
gAA gCT ATT CgT
CAC gTT Cg
 
BNIinAs
 
CTg TAg AAA ATC
CTA gCT ggA g
BNI-1 fragment 
nested PCR for protocol 3
108 bp
6
 
BNITMSARS1
 
TTA TCA CCC gCg
AAg AAg CT
 
BNITMSARAs2
 
CTC TAg TTg CAT 
gAC AgC CCT C
 
BNITMSARP
 
6-carboxyfluorescein-
TCg TgC gTg gAT Tgg
CTT TgA TgT-6-
carboxy-
 
N,N,N',N
 
'-
tetramethylrhodamin
BNI-1 fragment
5'-nuclease
real-time
77 bp
12.5 µl 2¬ reaction buffer†
3.6 mM magnesium sulfate†
1 µg bovine serum albumin§ 
240 nM probe
200 nM each primer 
0.6 µl reverse-transcriptase/
 
Taq
 
 DNA polymerase 
mixture†
5 µl RNA
25 µl total volume
45°C, 15 min
95°C, 3 min
40 cycles of 
95°C, 10 sec
58°C, 30 sec
Fluorescence measured 
at 58°C¶
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isolation and characterization
of a novel coronavirus
 
After six days of incubation (on March 21), a cyto-
pathic effect was seen on Vero-cell cultures inocu-
lated with sputum obtained from the index patient
on day 7. Twenty-four hours after a single passage,
nucleic acids were purified from the supernatant.
Random amplification was performed with 15 dif-
ferent PCRs under low-stringency conditions. We
had previously shown that this method is able to
detect unknown pathogens growing in cell culture
(unpublished data). To detect RNA viruses, an ini-
tial reverse-transcription step was included.
About 20 distinct DNA fragments were obtained
and sequenced. The resulting sequences were sub-
jected to BLAST data-base searches. Most of the
fragments matched human chromosome sequenc-
es, indicating that genetic material of the cultured
cells had been amplified (Vero cells are derived from
monkeys). Three of the fragments did not match
any nucleotide sequence in the data base. However,
when a translated BLAST search was performed
(comparison of the amino acid translation in all six
possible reading frames with the data base), these
fragments showed homology to coronavirus amino
acid sequences, indicating that a coronavirus had
been isolated. Two of the fragments were 300 nucle-
otides in length and identical in sequence, and the
third fragment was 90 nucleotides in length (se-
quences BNI-1 and BNI-2, respectively, as reported
on the Web site of the WHO network on March 25)
(Fig. 1A). Detailed sequence analysis revealed that
both fragments were located in the open reading
frame 1b of coronaviruses and did not overlap with
a 400-nucleotide coronavirus fragment identified
by colleagues at the Centers for Disease Control
and Prevention (CDC) (sequence CDC, reported on
the Web site of the WHO network on March 24)
(Fig. 1A).
There were sequences of six coronaviruses of all
phylogenetic lineages (groups 1, 2, and 3) in the se-
quence data base that overlapped with sequences
BNI-1 and BNI-2. All known sequences were only
distantly related to the new sequences (Fig. 1B).
The BNI-1 nucleotide sequence diverged from the
known sequences by between 39 percent (bovine
coronavirus) and 46 percent (porcine epidemic di-
arrhea virus). Such distances are typically found be-
tween different genetic lineages of coronaviruses.
 
7
 
A stable phylogeny was obtained with the BNI-1
fragment, indicating that the isolated coronavirus
segregates between genetic groups 2 and 3 (Fig. 1C).
The novel coronavirus isolate was termed FFM-ic
(for Frankfurt am Main index case).
To compare our isolate with that obtained by the
CDC, a fragment corresponding to the CDC frag-
ment was amplified from the cell-culture superna-
tant and sequenced. Both sequences were 100 per-
cent identical. Next, primers specifically targeting
the BNI-1 fragment and the CDC fragment were
synthesized. With the use of a long-range PCR pro-
tocol,
 
8
 
 a region extending from the CDC fragment
to the BNI-1 fragment was amplified. The obtained
fragment had the expected length of 3 kb. It was se-
quenced from both ends, and the sequences were
found to be identical to the CDC and BNI-1 se-
quences, respectively, demonstrating that the two
sequences were derived from a contiguous RNA
molecule and, thus, from the same virus. Since the
same virus was isolated from two independent cas-
es of SARS, and since there was serologic evidence
of an acute infection with this virus in our index pa-
tient and also in Contact 1 (as described below), it
was considered that the coronavirus might have a
role in causing SARS. Specific diagnostic assays
were therefore established for the detection of the
pathogen.
 
establishment of diagnostic pcr assays 
targeting the bni-1 fragment
 
A nested set of primers was designed within the
BNI-1 fragment (Fig. 1B). The outer set of primers
(protocol 3) (Table 1) detected the virus in clinical
specimens from the index patient and Contact 1,
who also had clinical signs of SARS (Table 2). Ad-
ditional specimens were positive on nested RT-PCR
(protocols 3 plus 5) (Tables 1 and 2). (The avail-
ability of PCR protocols at http://www.bni.
uni-hamburg.de/ was reported to the WHO network
on March 27 and to ProMed mail [an international
e-mail notification service for infectious-disease
outbreaks] on March 30.) To have a practical and
quantitative test, a real-time RT-PCR with a 5'-
nuclease probe was established (protocol 6) (Ta-
ble 1 and Fig. 1B). After optimization with the use
of quantified RNA transcribed in vitro, the assay re-
liably detected 10 copies of RNA per reaction, cor-
responding to 830 RNA molecules per milliliter of
specimen (Fig. 2). The sensitivities of nested and
real-time PCR were equivalent (Table 2). The spec-
ificity of the PCR with outer primers, of the nested
PCR, and of the real-time PCR (protocols 3, 3 plus 5,
and 6, respectively) (Table 1) was tested with the use
of RNA purified from cultures of bovine coronavi-
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rus, avian infectious coronavirus, porcine transmis-
sible gastroenteritis coronavirus, and human coro-
naviruses 229E and OC43. None of the PCR assays
cross-reacted with these viruses — a finding that is
consistent with their considerable genetic differenc-
es from the novel coronavirus.
Quantification of the viral RNA concentration in
clinical specimens from the index patient and Con-
tact 1 by real-time PCR revealed that the highest con-
centration — as high as 100 million copies per mil-
liliter — was present in sputum (Table 2). After
enrichment of virus by ultracentrifugation, viral
RNA was also detected in the serum of the index
patient, indicating the presence of low-level viremia
during symptomatic disease. Both the index patient
and Contact 1 had viral RNA in stool samples ob-
tained during late convalescence, suggesting that
virus may be shed in feces for prolonged periods.
To investigate whether the novel coronavirus was
prevalent in patients in Germany who had gastro-
intestinal symptoms, a collection of 54 stored
stool samples was tested with the use of the real-
time RT-PCR assay. None of the samples tested
positive.
The established PCR assays have also been used
to test respiratory samples from German patients
with symptoms and a travel history compatible with
SARS. So far, 67 samples from 55 patients have been
tested. One patient fulfilling the WHO criteria for
probable SARS was coronavirus-positive on PCR.
PCR protocols, as well as positive control material,
have been made available to laboratories worldwide.
 
testing of a panel of specimens 
from patients from asia with sars 
 
To provide evidence for the hypothesis that the nov-
el coronavirus is associated with SARS, further spec-
imens from patients with probable and suspected
SARS, as well as healthy contacts of patients affected
by the SARS epidemic in Hanoi, Vietnam, were test-
ed by nested PCR assays targeting the CDC and
BNI-1 fragments (protocols 2 plus 4 and 3 plus 5,
respectively) (Table 1). The prevalence of the virus
was 100 percent among patients with probable cas-
es of SARS and 23 percent among those with sus-
pected cases of SARS, whereas virus was not detect-
ed at all in the healthy contacts (Table 3). These
preliminary data may point to an association be-
tween the novel coronavirus and SARS. A total of
15 of the PCR products were sequenced — 7 from
the CDC fragment and 8 from the BNI-1 fragment.
All sequences were 100 percent identical to the cor-
responding CDC and BNI-1 sequences, providing
evidence of an epidemiologic link among these pa-
tients. Furthermore, these findings suggest that the
virus is rather stable genetically. 
 
serologic response
 
The serologic response to the coronavirus was test-
ed by a standard immunofluorescence technique
with serial serum samples from all three patients
and coronavirus FFM-ic–infected Vero cells. Spe-
cific IgG was not detected in serum from the index
patient and Contact 1 until day 9 and day 10, re-
spectively. Thereafter, the IgG titer increased to
1:1500 in the index patient and 1:250 in Contact 1.
No antibody response developed in Contact 2. 
 
Figure 1 (facing page). Genetic Characterization of the 
Novel Coronavirus. 
 
Panel A shows a schematic representation of coronavi-
rus genome organization (with bovine coronavirus, ac-
cession number NC_003045, as an example). Genes are 
depicted by brown arrows pointing in the direction of 
translation. Vertical arrows indicate the genomic location 
of the sequence fragments of the novel coronavirus 
found by the CDC and in our study (BNI-1 and BNI-2). 
UTR denotes untranslated region, orf open reading 
frame, NS nonstructural protein, HE hemagglutinin-
esterase glycoprotein, S spike glycoprotein, E small 
membrane gene, M membrane glycoprotein, and 
N nucleoprotein.
The top part of Panel B shows the nucleotide-sequence 
alignment of fragment BNI-1 with known coronaviruses. 
The lower part of Panel B shows the amino acid–sequence 
alignment of fragment BNI-1 with known coronaviruses. 
The nucleotide sequence was translated into single-letter 
amino acid code. Bovine-CV denotes bovine coronavirus, 
avian-IBV avian infectious bronchitis virus, murine-HV 
murine hepatitis virus, porcine-TGEV porcine transmis-
sible gastroenteritis coronavirus, porcine-EDV porcine 
epidemic diarrhea virus, and human CV-229E human 
coronavirus 229E. A dot indicates that the position is 
identical to the reference sequence (BNI-1). The oligonu-
cleotides for the nested reverse-transcriptase polymer-
ase chain reaction (RT-PCR, brown) and the real-time 
RT-PCR (purple) are shown as arrows pointing in the 
direction of their elongation.
In Panel C, a phylogenetic tree shows relations among 
coronavirus polymerase gene fragments (corresponding 
to BNI-1) according to the neighbor-joining method. The 
maximum likelihood method revealed the same rela-
tions (data not shown). Genetic distances are indicated 
by the lengths of the branches. Analyses were performed 
on a bootstrapped data set (100 replicates). In addition 
to the coronavirus isolate FFM-ic, avian infectious bron-
chitis virus (IBR31131), bovine coronavirus (AF220295), 
human coronavirus 229E (12175745), murine hepatitis 
virus (9629812), porcine epidemic diarrhea virus 
(19387576), and porcine transmissible gastroenteritis 
coronavirus (13399293) were included in the analysis. 
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A
B
C
CDC
400 nt
BNI-1
300 nt
BNI-2
90 nt
310281
3' UTR
5' UTR NS S E
M
N12.7 kD NS
orf 1ab 4.9 kD NS
orf 1a HE 4.8 kD NS
90
100
99
81
Porcine transmissible
gastroenteritis coronavirus
Murine hepatitis virus
Porcine epidemic
diarrhea virus
Human coronavirus 229E
Avian infectious bronchitis virus
FFM-ic
Bovine coronavirus
BNITMS1
BNITMAs2BNITMP
BNIinS
BNIinAs
BNIoutS2
BNIoutAs
BNI-1
Bovine-CV
Avian-IBV
Murine-HV
Porcine-TGEV
Human-CV-229E
Porcine-EDV
10
TACCGTAGAC
..TTCA...T
..TAAACAT.
..TTCGC.G.
..TGC..ATG
..TGAACATG
..TGAGCATG
20
TCATCTCTAT
.A..A..AC.
.T..T...C.
.T..A..AC.
.......ATA
.G..T..ATA
.T.....GT.
30
GATGGGTTTC
C........T
.T.A..A...
C.....A...
T.....A...
T.........
T.........
40
AAAATGAATT
...C..G..G
..G....G.G
..GC.TG.C.
.GGT.TG.AG
.GGT.TG..G
CGTT.TG..A
50
ACCAAGTCAA
TTACCC.TG.
TTA.T..TG.
TGACCC.TG.
C.A.CA.ACC
TTAGCA.GCC
TTA.CA.ACC
60
TGGTTACCCT
...G..TTG.
A..C.G..AC
......TTG.
A..C..T.AC
....AGT.A.
CAACC...AC
70
AATATGTTTA
..GC.T....
..C.......
..GC......
.CAC.A..CT
.G.T....CT
.C.C.C...T
80
TCACCCGCGA
.A..TAAA..
.A..A..T..
.A..TA.A..
G...G..A..
GT..TA.A..
G...A.....
90
AGAAGCTATT
.......G..
T..G..A..C
T........C
TTTT.....G
CTTT..C..G
CTTT..C..G
100
CGTCACGTTC
AAA.G...G.
..CA.T..AA
AAA.GT...A
...A.T...A
.....T..CA
..CA.T...A
BNI-1
Bovine-CV
Avian-IBV
Murine-HV
Porcine-TGEV
Human-CV-229E
Porcine-EDV
110
GTGCGTGGAT
....T...G.
.A.GT...G.
.A..C...G.
.A..A...C.
.A.GT...T.
.A.GT...T.
120
TGGCTTTGAT
..........
A..T......
......C...
...G.....C
A..AA.G...
G..T.....C
130
GTAGAGGGCT
.CT..A..TG
.....A.CAA
.C...A..TG
..T..A..TG
..G..A..TG
..T..A..AG
140
GTCATGCAAC
C......C..
CA.....TTG
CC.....G.T
CA....TCTG
CA....TC..
CA....TTGT
150
TAGAGATGCT
GC.T...AGC
.G.CAC.AAC
AC.T...AGC
.G.T...AA.
AG.T..CAA.
.G.CTC.AAC
160
GTGGGTACTA
A.T..G..A.
A.T.......
A.T..G..A.
..T..A....
..T..C....
..C.....A.
170
ACCTACCTCT
.TT.C..A..
....G...T.
.TT.C..AT.
.TG....AT.
.TG.......
.TG.C..AT.
180
CCAGCTAGGA
T..AT....G
T..AG....T
A..AT....C
A.....G..T
A..AG.T..T
G..AT....G
190
TTTTCTACAG
.....C....
..C.....T.
.....G..T.
..C..A.AC.
.....C.AT.
.......AC.
200
GTGTTAACTT
.AA..G.T..
...CAG....
.AA..G.T..
....GG.T..
.....G.T..
.....G.T..
BNI-1
Bovine-CV
Avian-IBV
Murine-HV
Porcine-TGEV
Human-CV-229E
Porcine-EDV
210
AGTAGCTGTA
T..T.TG.A.
T....TCACG
T..T.TC.A.
T....TGCA.
T......CA.
T..T.TCAG.
220
CCGACTGGTT
G.C.......
..TGAG..AC
G.C.....AA
A.TGAA..A.
..TGAA....
..TGAA....
230
ATGTTGACAC
TGT...CTGA
T...A..T..
TGT...CTGA
G....ATT..
G....CTA..
GC....TA..
240
TGAAAATAAC
.AG.G..GGT
.TC..TAGG.
GAG.G..GGT
......AGGT
AA.C.C.GG.
...GTC.GGT
250
ACAGAATTCA
TACAGC..T.
.ATA.T..TG
TAT.TC..T.
.ATAGCA.TG
.GT.TTG.A.
GACT.CA.T.
260
CCAGAGTTAA
AA.AG.C.GT
AGCCT..G..
AA.AG.CAGC
AGGTT..A..
AACCT...CG
AACCC..C.G
270
TGCAAAACCT
G..T...G..
.T.T...G.A
C...CG.G..
A...CG.G.A
...TCGTG.A
A..TCGTG..
280
CCACCAGGTG
..T..T....
..T.......
..T..T..C.
..........
.....T..A.
........G.
290
ACCAGTTTAA
.A..A.....
.A..A.....
.A..A.....
.G..A...GC
.A..A..C.C
.A..A..CGC
300
ACATCTTATA
G.....C..C
C..CT.G.G.
...C.....C
...CT.G..T
T..CA..G..
...C...T.G
BNI-1
Bovine-CV
Murine-HV
Avian-IBV
Porcine-TGEV
Human-CV-229E
Porcine-EDV
10
YRRLISMMGF
.S....L...
.S....L...
.KH...LL..
.ANV..Y...
.EHV..Y...
.EHV..F...
20
KMNYQVNGYP
.LDVTLD..C
.LDLTLD..C
..SVN.E.CH
RFEANIP..H
RFDVSMP.SH
RFDINIPNHH
30
NMFITREEAI
KL...K...V
KL....D...
......D...
TL.C..DF.M
SL.C..DF.M
TL.C..DF.M
40
RHVRAWIGFD
KR....V...
KR....V... 
.N..G.V...
.N....L...
....G.L.M.
.N..G.L...
50
VEGCHATRDA
A..A.....S
A..A..I..S
..AT..CGTN
...A.VCG.N
...A.V.G.N
...A.VVGSN
60
VGTNLPLQLG
I...F.....
I...F.....
I.....F.V.
....V.....
....V...V.
....V.....
70
FSTGVNLVAV
....IDF.VE
....IDF.VE
....ADF.VT
..N..DF.VQ
..N..DF..Q
..N..DF.VR
80
PTGYVDTENN
A..LFADRDG
A..MFAERDG
.E.L...SIG
TE.C.I..KG
.E.C.L.NTG
.E.C.V..SG
90
TEFTRVNAKP
YS.KKAV..A
YV.KKAA.RA
NN.EP..S.A
NSIEV.K.RA
SVVKP.R.RA
DYIKP.R.RA
100
PPGDQFKHLI
...E......
...E......
...E..N..R
...E..A...
...E..T.IV
...E..A..L
Group 1
Nucleotide sequences
Amino acid sequences
Group 2
Group 3
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The principal finding of the study is the identifica-
tion of a novel coronavirus in patients with SARS. It
appears that patients with SARS are acutely infected
with this virus, since they have virus-specific IgG
seroconversion. The high rate of positivity among
patients with probable cases during an outbreak of
SARS in Hanoi, in conjunction with the complete
negativity among all healthy contacts of patients
affected by the same outbreak, provides evidence of
an association between the disease and the presence
of this novel virus. The involvement of a coronavirus
in a respiratory disease would not be without prec-
edent: the two human coronaviruses are known to
cause mild respiratory illness.
 
9
 
 One should bear in
mind, however, that in the past, viruses have been
initially isolated from patients with a specific dis-
ease but subsequent investigations revealed no actu-
al association at all.
 
10,11
 
 Thus, larger studies with
appropriate control groups are needed to verify or
eliminate our hypothesis about the cause of SARS.
The assays that have been established provide an
excellent tool for such studies. It should also be
discussion
 
* PCR denotes polymerase chain reaction, BAL bronchoalveolar-lavage fluid, and ND not done. Plus signs indicate posi-
tive results, and minus signs negative results.
† Values are copies per milliliter. 
‡ Sample was tested 24 hours after passage. 
§ Test was positive but below the limit of reliable quantification (800 copies per milliliter).
¶Test was performed after ultracentrifugation of 2 ml of plasma.
 
Table 2. Detection of the Novel Coronavirus in Various Clinical Specimens with the Use of Different PCR Assays.* 
Sample Result on PCR Assay
 
IN-2
IN-4
SAR1S
SAR1As
BNIoutS2
BNIoutAs
BNIoutS2
BNIoutAs
and Nested
BNIinS
BNIinAs Real-Time PCR†
Cell culture‡ + + + + 8.3¬10
 
6
 
Index patient
 
 
Sputum, day 9 ¡ + + + 1.0¬10
 
8
 
Throat swab, day 9 ¡ ¡ ¡ + <800§
Nasal swab, day 9 ¡ ¡ ¡ ¡ <800§
Plasma, day 9 ¡ ¡ ¡ + 190¶
BAL, day 11 ¡ + + + 4.1¬10
 
5
 
Stool, day 25 ND ND ND ND +
 
Contact 1
 
Sputum, day 3 ¡ + + + 6.3¬10
 
4
 
Throat swab, day 3 ¡ ¡ ¡ ¡ ¡
Nasal swab, day 3 ¡ ¡ ¡ ¡ ¡
Plasma, day 3 ¡ ¡ ¡ ¡ ¡¶
Stool, day 19 ND ND ND ND +
 
Contact 2
 
Sputum, day 5 ¡ ¡ ¡ ¡ ¡
Plasma, day 5 ¡ ¡ ¡ ¡ ¡¶
Stool, day 21 ND ND ND ND ¡
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taken into account that antigen that was present in
primary cultures was used to detect the antibody
response, and it remains to be firmly established
that this response is indeed directed against the
novel coronavirus rather than against an unknown
agent that might have been isolated simultaneous-
ly. This possibility could be tested with the use of
plaque-purified virus or recombinant proteins as
antigen. 
By testing for a broad range of known pathogens,
we also obtained evidence for infection with para-
myxoviruses and 
 
C. pneumoniae
 
. Paramyxoviruses —
in particular, human metapneumovirus, which was
previously implicated in SARS
 
12
 
 — could be largely
ruled out by further investigation. Infection with
chlamydia was confirmed in several assays. Howev-
er, chlamydia was not found in other patients with
SARS.
 
3
 
 Hence, it remains unclear whether these
pathogens have a role as causative factors or cofac-
tors in SARS. 
The quantitative analysis of various clinical spec-
imens from the patients with SARS reveals interest-
ing features of the viral infection. First, the viral
RNA concentration in sputum was high in both pa-
tients, suggesting that shedding of the virus from
the respiratory tract could be the primary route of
transmission. The extremely high RNA concentra-
tions found in sputum from the index patient would
be consistent with a high level of contagiousness of
the SARS agent. The detection of low amounts of vi-
ral RNA in serum from the index patient on day 9
would be compatible with a long viremic phase,
suggesting that replication does not occur only in
the respiratory tract. The elevated levels of aspartate
aminotransferase and lactate dehydrogenase
 
3
 
 in-
deed suggest that the agent causing SARS is also
replicating outside the respiratory tract. The pres-
ence of viral RNA in stool of the patients late during
convalescence is reminiscent of characteristics of
other coronaviruses.
 
13
 
 Shedding of the virus in feces
may be an additional source of spreading, provided
that the virus is stable in this environment. From a
diagnostic point of view, it is important to note that
nasal and throat swabs seem less suitable for diag-
nosis, since these materials contain considerably
less viral RNA than sputum, and the virus may es-
cape detection if only these materials are tested.
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Figure 2. Real-Time Polymerase Chain Reaction (PCR) Targeting the BNI-1 
Fragment of the Novel Coronavirus.
 
The plot shows an amplification of a limiting-dilution series of standard RNA 
transcribed in vitro. The y axis indicates the fluorescence signal recorded in 
each amplification cycle, as plotted along the x axis. Numbers at the right 
show the number of copies of RNA per reaction. The inset graph presents a 
standard curve showing the relation between the concentration in standard 
samples (on the x axis) and the number of cycles it took to generate a fluores-
cence signal in the respective samples (on the y axis). The standard curve al-
lows quantification of coronavirus RNA in clinical samples. 
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* RT-PCR denotes reverse-transcriptase polymerase chain reaction.
† Samples were from the lower respiratory tract in five patients and nasopharyn-
geal swabs in one patient (all positive); samples were obtained 3 to 13 days 
after the onset of illness.
‡ Nasopharyngeal samples from 13 patients were used; they were obtained 3 to 
12 days after the onset of illness.
 
Table 3. Proportion of Patients with a Positive RT-PCR Result for Coronavirus.*
Group
Mean No. 
of Samples 
per Patient
Fraction of Patients Testing 
Positive
 
IN-6/IN-7 
and Nested
SAR1S/
SAR1As
BNIoutS2/
BNIoutAs
and Nested 
BNIinS/BNIinAs
Patients with probable SARS † 2.2 5/5 5/5
Patients with suspected SARS‡ 1.3 3/13 3/13
Contacts 1.0 0/21 0/21
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